Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro

Experimental Hematology(2020)10.1016/j.exphem.2020.05.001Source: DataRank Database

Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro is a research paper published in Experimental Hematology (2020). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 0.82)OA: hybridTopics (57)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Aixia Dou ORCID,Saran Feng,Ashley Roman-Rivera,Caleb Hawkins,Lauren Lawley

Live enrichment

PubMed:32437909 PMC:PMC7335335 OpenAlex:https://openalex.org/W3023070172

NCATS NIH HHS

Grant: UL1 TR001863

NCI NIH HHS

Grant: R01 CA218076

NCI NIH HHS

Grant: R50 CA211404

National Science Foundation

Grant: 1736150

RII Track-2 FEC-Genome to fitness: An Analysis of the Stress Response in Peromyscus

National Institutes of Health

Grant: 5R01CA218076-02

Targeting the p62 signalosome in leukemia.

St. Baldrick's Foundation

National Institutes of Health

Aplastic Anemia and MDS International Foundation

National Science Foundation

FWCI

0.82

Citation Percentile

0.7%

Citation Trend

2020

2021

2022

2023

2024

2025

hybridLicense: cc-by-nc-nd

journalhttp://www.exphem.org/article/S0301472X20301430/pdf

publisherhttp://www.exphem.org/article/S0301472X20301430/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0301472X20301430?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0301472X20301430?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.exphem.2020.05.001

Fields of Study

Signaling Pathways in DiseaseProtein Degradation and InhibitorsMultiple Myeloma Research and Treatments0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

LenalidomideAnimalsDNA-Binding ProteinsHumansMuscle ProteinsMyelodysplastic SyndromesNeoplasm ProteinsLeukemia, Myeloid, AcuteUp-RegulationGene Expression Regulation, LeukemicCyclosporineMice, Inbred NODApoptosisDrug Resistance, NeoplasmXenograft Model Antitumor AssaysCell Line, TumorMiceIkaros Transcription Factor

Keywords

Downregulation and upregulationMyeloid leukemiaCancer researchChemistryCalcineurinLenalidomideChemosensitizerPharmacologyImmunologyCytotoxicityIn vitroBiologyMedicineTransplantationInternal medicineBiochemistryGene Expression Regulation, LeukemicMuscle ProteinsApoptosisXenograft Model Antitumor AssaysNeoplasm ProteinsUp-RegulationDNA-Binding ProteinsIkaros Transcription FactorLeukemia, Myeloid, AcuteMiceDrug Resistance, NeoplasmMice, Inbred NODCell Line, TumorMyelodysplastic SyndromesCyclosporineAnimalsHumans

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being